NanoEcho AB (publ) is a Swedish medical technology company founded in 2013 and headquartered in Lund, Sweden. The company specializes in developing innovative diagnostic methods to identify the spread of rectal cancer to nearby lymph nodes by integrating nanotechnology with modern ultrasound imaging. This focus aims to enhance cancer diagnostics specifically for rectal cancer. In 2024, NanoEcho AB conducted an initial public offering (IPO) on the Nasdaq Stockholm First North exchange, trading under the ticker symbol NANECH. The IPO was priced at 0.14 SEK per share, generating approximately 17.6 million SEK in capital. As of August 2026, the company has a market capitalization of approximately 13.92 million SEK, with around 470.20 million shares outstanding. NanoEcho AB employs around 5 individuals. Additionally, its technology may have potential applications in other medical areas, such as prostate cancer detection and stem cell therapies.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
NanoEcho AB (publ)'s offering is currently approved on OTHER. NanoEcho AB (publ) is headquartered in Sweden. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with NanoEcho AB (publ).
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/nanoecho-ab-publ" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="NanoEcho AB (publ) — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/nanoecho-ab-publ?theme=light as the src instead.
https://www.discoveripo.com/ipo/nanoecho-ab-publ/opengraph-image
NanoEcho AB (publ) IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/nanoecho-ab-publ?utm_source=embed&utm_medium=text&utm_campaign=nanoecho-ab-publ
Get emailed when NanoEcho AB (publ)'s terms, price, or expected date change — no weekly noise, just this company.
NanoEcho AB (publ) is listing on OTHER.
NanoEcho AB (publ) is a Swedish medical technology company founded in 2013 and headquartered in Lund, Sweden. The company specializes in developing innovative diagnostic methods to identify the spread of rectal cancer to nearby lymph nodes by integrating nanotechnology with modern ultrasound imaging. This focus aims to enhance cancer diagnostics specifically for rectal cancer. In 2024, NanoEcho AB conducted an initial public offering (IPO) on the Nasdaq Stockholm First North exchange, trading under the ticker symbol NANECH. The IPO was priced at 0.14 SEK per share, generating approximately 17.6 million SEK in capital. As of August 2026, the company has a market capitalization of approximately 13.92 million SEK, with around 470.20 million shares outstanding. NanoEcho AB employs around 5 individuals. Additionally, its technology may have potential applications in other medical areas, such as prostate cancer detection and stem cell therapies.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy